Sanofi may rebid for Ocular Therapeutix, Inc. to boost retinal therapeutics ahead of Dupixent patent expiry. Click for more ...

Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious ...

The study found significant intra-group CMT reductions in the DEX-I group, with a higher percentage reduction than the ...

Panelists discuss how emerging therapies—including TKIs, sustained-release implants, and gene therapy—may reduce treatment ...

Full-year 2025 preliminary1 U.S. net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) total injection demand grew 17% ...

Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse or prevent blindness, today announced that dosing is complete in ...

Switching from aflibercept to ranibizumab biosimilars maintains stability in nAMD treatment, offering a cost-effective ...

What Is Eylea HD, and Why Does It Matter? Eylea HD (aflibercept) is an injectable medicine used to treat certain eye conditions that can lead to vision loss. It works by blocking a protein called VEGF ...

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals Inc.’s (NASDAQ: REGN) Eylea HD (aflibercept) Injection 8 mg for patients with macular edema following ...

First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period ...

TARRYTOWN, N.Y., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD ® (aflibercept) ...